New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure

Participating Faculty

July 1st 1998

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

July 1st 1998

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

BySheldon G. Sheps, MD,Henry R. Black, MD,Jerome D. Cohen, MD,Norman Kaplan, MD,Keith C. Ferdinand, MD

July 1st 1998

Gene Polymorphism Influences Response to Angiotensin Blockade

ByGershan K. Davis, MD

July 1st 1998

New Drug Class Offers Benefits in Heart Failure

ByEdward P. Havranek, MD

July 1st 1998

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

ByMarvin A. Konstam, MD

July 1st 1998

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

BySalim Yusuf, DPhil

July 1st 1998

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

ByNorman K. Hollenberg, MD

July 1st 1998

What are the Pharmacological Differences Between Angiotensin II Antagonists

ByThomas Unger, MD

July 1st 1998

Clinical Implications of Differences Between Angiotensin II Antagonists

ByPeter S. Sever, MD,Giuseppe Mancia, MD

July 1st 1998

Exploring the Benefits Beyond Blood Pressure Control

ByHans Lithell, MD,Luis Ruilope, MD

July 1st 1998

How Far Have We Come in Treating Congestive Heart Failure?

ByBertram Pitt, MD

July 1st 1998

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

ByAlan H. Gradman, MD

July 1st 1998

Angiotensin Receptor Blockers: Cardio-renal Implications in Patients with Congestive Heart Failure

ByDominic A. Sica, MD

July 1st 1998

Selected Abstracts

July 1st 1998

Bibliography

July 1st 1998

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure

Participating Faculty

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Gene Polymorphism Influences Response to Angiotensin Blockade

New Drug Class Offers Benefits in Heart Failure

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

What are the Pharmacological Differences Between Angiotensin II Antagonists

Clinical Implications of Differences Between Angiotensin II Antagonists

Exploring the Benefits Beyond Blood Pressure Control

How Far Have We Come in Treating Congestive Heart Failure?

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Angiotensin Receptor Blockers: Cardio-renal Implications in Patients with Congestive Heart Failure

Selected Abstracts

Bibliography

Trending on AJMC

Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD

Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts

UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes

Insurance Barriers Tied to Missed Long-Acting PrEP Starts

The Bispecifics Network:

Advancing Bispecific Care Delivery in Community Oncology

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure

Participating Faculty

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Gene Polymorphism Influences Response to Angiotensin Blockade

New Drug Class Offers Benefits in Heart Failure

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

What are the Pharmacological Differences Between Angiotensin II Antagonists

Clinical Implications of Differences Between Angiotensin II Antagonists

Exploring the Benefits Beyond Blood Pressure Control

How Far Have We Come in Treating Congestive Heart Failure?

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Angiotensin Receptor Blockers: Cardio-renal Implications in Patients with Congestive Heart Failure

Selected Abstracts

Bibliography

Trending on AJMC

Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD

Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts

UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes

Insurance Barriers Tied to Missed Long-Acting PrEP Starts